MD, Cardiologist, PhD clinical pharmacology (Université de Lorraine, Nancy, Université Claude Bernard, Lyon, France and Oxford MRC, UK). Emeritus Professor of Therapeutics at the Université of Lorraine, Past Director of the Inserm Clinical Investigation Center at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. 2019 Eugene Braunwald Scolar at Harvard Medical School. As a clinical trialist Dr Zannad has significantly contributed to building most of the trial-based evidence supporting modern heart failure drug therapy, including mineralocorticoid receptor antagonists, beta-blockers, and SGLT2inhibitors, as well the management of major comorbid conditions in heart failure, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, and chronic kidney disease. As a clinical pharmacologist, he developed expertise in biomarker science, exploring the mechanisms of action of heart failure drugs. Dr Zannad served as Chairman of the French Society of Hypertension and of the Working Group on Pharmacology and Drug Therapy of the European Society of Cardiology (ESC). He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, a global think tank dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Asia and the Middle East. Dr Zannad is a Highly Cited Researcher Award Recipient in the field of Clinical Medicine, with currently an H index of 155 based on 1200 peer-reviewed publications which received over 300 000 citations. He received the 2014 European Society of Hypertension Paul Milliez Award, the 2017 ESC-Heart Failure Association Lifetime Achievement Award and the 2022 Heart Failure society of Americas international Honorary Fellowship Award.